The startup accelerator Tesonet has announced an additional investment into the medicinal and edible mushroom farm MISHKAY Biotech, better known in the Lithuanian market as Pjaunu Grybą.
Having made its first investment in 2023 with a pledge to double it, the accelerator has eventually decided to multiply it three times, Tesonet stated in a press release. „Growing sustainably, MISHKAY Biotech managed to exceed all expectations and is now facing the pleasant challenge of demand for their products overshooting supply – the result of a bold and evidence-based vision. Our interactions with the broader community of longevity researchers and businesses have clarified for us the importance of support and investment in this vertical.
"This is a Lithuanian product, created in Lithuania, which makes us proud of the contribution we're making to its further development by increasing our investment," said Eimantas Sabaliauskas, co-founder of Tesonet.
The invested funds will be used for completing the construction of an R&D lab and expanding medicinal mushroom production capacities, as well as developing a B2B product line and pursuing innovations.
Read the full article on Delfi.